Sunobinop
Phase 2Small molecule
Sunobinop is one of 9 small molecule programs targeting Alcohol Use Disorder. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Alcohol Use Disorder
#DrugCompanyPhaseTrials
1Revia
TevaPhase 2
Psilocybin
COMPASS PathwaysPhase 3
Nimotop
AAzurity Pharmaceuticals
Phase 2
LY3537031
Eli LillyPhase 3
Aldactone
PfizerPhase 1
Mazdutide
Eli LillyPhase 2
Glucagon-Like Peptide-1 Agonist (GLP-1)
Johnson & JohnsonPhase 2
Sunobinop
IImbrium Therapeutics
Phase 2
18f-Pf-06445974
NNational Institute of Mental Health (NIMH)
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sunobinop. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImbrium Therapeutics